Display Settings:

Format

Send to:

Choose Destination
    Expert Rev Anticancer Ther. 2007 Aug;7(8):1123-34.

    Quality of life and adjuvant systemic therapy for early-stage breast cancer.

    Source

    NHMRC Clinical Trials Centre, Building M02F, University of Sydney, NSW 2006, Australia. Peter.Grimison@ctc.usyd.edu.au

    Abstract

    Adjuvant chemotherapy and hormonal therapy reduce the risk of recurrence and death due to breast cancer, but often at considerable cost to the health-related quality of life (HRQL) of patients. The short-term effects of chemotherapy on HRQL are well known and are accepted by most patients for modest gains in survival. The long-term effects of chemotherapy-induced menopause and hormonal therapy on HRQL are poorly recognized. Vasomotor symptoms and altered sexual function are common, distressing and inadequately treated. HRQL information is helpful in describing likely effects of adjuvant treatment, facilitating informed decision-making, identifying health problems to guide research into potential solutions, guiding treatment strategies for interventions with equivalent survival and guiding resource allocation. New technologies will make HRQL information increasingly available for individual patient care.

    PMID:
    18028021
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Atypon

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk